Company / Cash & Equivalents
Syndax Pharmaceuticals Inc Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$134.9M
FY2025
5-year range
$74.4M / $295.4M
FY2021-FY2025
Trend
-12.4%
vs FY2024
Sector context
#119 of 207
Health Care
What the data says
At $135M, Syndax Pharmaceuticals Inc's cash & equivalents ranks #119 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $10M in FY2016 to $295M in FY2023.
Based on SEC 10-K filings.
$135M in FY2025 with a 5-year CAGR of +40.5%.
Declined from $295M to $135M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +22.0%
- 5-Year CAGR
- +40.5%
- 10-Year CAGR
- -
Sector benchmark
#119 of 207 in Health CareTop 57% of 207This company $134.9M Sector average $669.5M
▼
-79.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +40.5%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 12.4% year-over-year.
- Ranks #119 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $134.9M | -12.4% |
| FY2024 | $154.1M | -47.8% |
| FY2023 | $295.4M | +297.3% |
| FY2022 | $74.4M | -35.5% |
| FY2021 | $115.2M | +368.3% |
| FY2020 | $24.6M | -27.1% |
| FY2019 | $33.8M | -4.0% |
| FY2018 | $35.2M | +47.5% |
| FY2017 | $23.8M | +138.2% |
| FY2016 | $10.0M | -56.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026